SCHEMBL31686263

SCHEMBL31686263

CS(=O)(=O)c1nnccc1C(N)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.37
SIRT3 Q9NTG7 1/20 0.37
CASP1 P29466 2/20 0.35
CDC7 O00311 1/20 0.34
LMNA P02545 1/20 0.33
KDM4E B2RXH2 6/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
PARP1 P09874 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA13 Q8N1Q1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9953506 0.75 PARP1 (0.50) TDP1LMNAKDM4EL3MBTL1PARP1
SCHEMBL28322999 0.73 NNMT (0.46) TDP1SIRT3CASP1CDC7KDM4E
SCHEMBL27202095 0.71 LRRK2 (0.37) LMNAKDM4ELRRK2MEN1KMT2A
SCHEMBL164572 0.71 SIRT3 (0.38) TDP1SIRT3CASP1CDC7KDM4E
SCHEMBL10877795 0.71 KDM4E (0.41) TDP1SIRT3CASP1CDC7KDM4E
SCHEMBL28309038 0.71 SIRT3 (0.38) TDP1SIRT3CASP1KDM4EL3MBTL1
SCHEMBL28296833 0.71 KDM4E (0.32) KDM4EL3MBTL1ALDH1A1
SCHEMBL10695792 0.71 L3MBTL1 (0.31) L3MBTL1
SCHEMBL31092388 0.69 CASP1 (0.49) TDP1SIRT3CASP1KDM4EL3MBTL1
SCHEMBL31092393 0.69 CASP1 (0.40) TDP1SIRT3CASP1CDC7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595244-B2 Small molecule inhibitors of mammalian SLC6A19 function JNANA THERAPEUTICS INC. (US) 2026-04-07 US disclosed
US-20250289797-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. 2025-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289797-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION SLC18A2, SLC6A19, SLC1A1 TDP1 1116/4885SIRT3 3687/4885CASP1 4866/4885
US-12595244-B2 Small molecule inhibitors of mammalian SLC6A19 function SLC6A19, SLC6A15, SLC19A1 TDP1 1306/4885SIRT3 3570/4885CASP1 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.